Agenda

Friday, 6 December 2024

Unconditional support of Ocular Therapeutix

Retina Futura 2024 Program Chairs:

  • Stanislao Rizzo, Italy
  • Jeffrey Heier, USA
  • Peter Kaiser, USA
  • Lejla Vajzovic, USA

SESSION 1 | 11:00 – 12:30

11:00 |
Introduction by the Program Chairs

11:05 -11:35
Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates

11:05 |
EB-105: A Novel Trispecific Fusion Antibody for Retinal Disease
Carl Awh

11:09 |
Impact of GLP-1 Receptor Agonists on Chronic Eye Conditions Including Non-Exudative AMD
Aleksandra Rachitskaya

11:13 |
Glibenclamide is Neuroprotectant Against AMD
Francine Behar-Cohen

11:17 |
An overview of ONS-5010 (bevacizumab gamma) as ophthalmic formulation of bevacizumab
Albert Augustin

11:21 |
EYP-1901 for Maintenance Treatment of Neovascular AMD: Phase 2 DAVIO 2 
End-of-Study 12-Month Results
Carl D. Regillo

11:25 |
Beyond VEGF-A inhibition: will blocking VEGF-C and VEGF-D lead to better outcomes?
Adnan Tufail

11:29 |
OTX-TKI–The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
Diana Do

11:33 |
Panel Discussion & Transition to next Session
Program Chairs & Panel
11:38 -12:00
Innovations in siRNA and Gene Therapies for AMD

11:38 |
Gene Therapy for Neovascular AMD by Subretinal and Suprachoroidal Delivery of 
ABBV-RGX-314 Including Fellow Eye Data
Sophie J. Bakri

11:42 |
Efficacy and Safety of Ixoberogene Intravitreal Gene Therapy for Neovascular AMD: Phase 2 LUNA Trial Study Results
Dominik Fischer

11:46 |
First Results of the Phase 2 BETTER Trial Using Intravitreal ISTH0036: a Selective TGF-β2–Blocking Antisense in AMD and DME
Marion Munk

11:50 |
Development of 4D-150 for Retinal Vascular Diseases
Carlos Quezada Ruiz

11:54 |
Panel Discussion & Transition to next Session
Program Chairs & Panel

12:00 -12:20
Spotlight on Inherited Retinal Diseases (IRDs)

12:00 |
Gildeuretinol Slows Progression of Stargardt Disease: The TEASE Program
Philip Ferrone

12:04 |
Subretinal Gene Therapy AGTC-501 for X-Linked Retinitis Pigmentosa XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Results
Paulo Stanga

12:08 |
Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN)
Jordi Mones

12:12 |
Panel Discussion
Program Chairs & Panel

12:20 -12:30
Late breakers

SESSION 2 | 13:30 – 14:45

13:30 -14:00
Advancements in Geographic Atrophy (GA): Current and Emerging Therapies

13:30 |
Oral Medications for Dry AMD
Charles DeBoer

13:34 |
Glycomimetic Nanoparticle AVD-104 in the Management of GA From AMD: Anatomic Outcomes
Tarek Hassan

13:38 |
OpRegen: Embryonic Stem Cell Derived Therapy for Dry AMD and GA
Christopher D. Riemann

13:42 |
Fas Inhibition with ONL1204 for the Treatment of GA Secondary to AMD: Results from a Phase 1b Study
Lejla Vajzovic

13:46 |
C1q inhibition with ANX007: Functional and Structural Protection in dry AMD / GA via a Novel Neuroprotective Mechanism
Peter Kaiser

13:50 |
Panel Discussion & Transition to next Session
Program Chairs & Panel

14:00 -14:30
Diabetic Retinal Diseases and Retinal Detachment

14:00 |
Outcomes of the HORNBILL Study: Phase 1/2a Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
Quan Dong Nguyen

14:04 |
OCS-01: An emerging topical treatment option for DME
Anat Loewenstein

14:08 |
DURAVYU in diabetic eye disease
Ramiro Ribeiro

14:12 |
HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
Dilsher Dhoot

14:16 |
Intravitreal Fas inhibitor ONL1204 for Macula-off Rhegmatogenous Retinal Detachment: Results of a Phase 2 Clinical Trial
Durga Borkar

14:20 |
Panel Discussion and Transition
Program Chairs & Panel

14:30 -14:45
Late breakers

14:30 |
ABBV-RGX-314: A one-time in-office gene therapy for the treatment of diabetic retinopathy and the prevention of DME, PDR & other vision threatening complications; the Phase II ALTITUDE® Study
Lejla Vajzovic

14:34 |
New clinical and nonclinical analyses reveal silicone oil is associated with intraocular inflammation following intravitreal administration of Abicipar Pegol
Peter Kaiser

SESSION AWARDS | 14:45 - 15:00

Newcomer of the Year Award

Most Innovative Science Award

Most Clinically Impactful Award

To top